Mutated factor X polypeptides and uses thereof for the treatment of haemophilia
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 9, 2020
Grant Date -
Dec 28, 2017
app pub date -
Jan 6, 2016
filing date -
Jan 7, 2015
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide wherein the heavy chain comprises at least one mutation selected from the group consisting of: —the mutation which consists of the substitution of the glutamic acid residue (E) at position 255 of Seq. ID No. 1 by a glutamine residue (Q), an asparagine residue (N), a serine residue (S), an alanine residue (A), or a tyrosine residue (Y); —the mutation which consists of the substitution of the glutamic acid residue (E) at position 256 of Seq. ID No. 1 by a glutamine residue (Q); and —the mutation which consists of the substitution of the glutamic acid residue (E) at position 258 of Seq. ID No. 1 by a glutamine residue (Q).
First Claim
Other Claims data not available
Family
International Classification(s)
- 2016 Application Filing Year
- A61K Class
- 19101 Applications Filed
- 13019 Patents Issued To-Date
- 68.16 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 5 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Dec 9, 2027 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Dec 9, 2031 |
